Haematology evidence: balancing laboratory and clinical work for the Portfolio Pathway

The dual nature of haematology

UK haematology sits at the intersection of two worlds that most other specialties occupy separately. A haematology Consultant runs or leads a diagnostic laboratory - responsible for blood morphology, bone marrow reporting, coagulation interpretation, and blood bank - while simultaneously managing patients with haematological malignancies, bleeding disorders, thrombosis, sickle cell disease, and aplastic anaemia. These two roles are not separate: the morphology result you authorise in the morning feeds directly into the MDT discussion you chair in the afternoon.

This dual nature is what makes haematology Portfolio Pathway applications more complex than most. The evidence base is large, but assembling it requires conscious attention to documentation in both clinical worlds throughout your career. Neither side can be improvised retrospectively in the months before submission. The doctors who submit strongest haematology applications are those who have maintained parallel evidence streams for years, not those who sprint to collect retrospective records.

The haematology Portfolio Pathway overview covers the application structure, the FRCPath requirement, the curriculum framework, and a realistic timeline. This article goes deeper into the specific evidence strategies for each pillar. If you have not read the overview first, start there for the broader picture before returning here.

A note on the FRCPath upfront: holding FRCPath in Haematology by examination is a mandatory requirement for the haematology Portfolio Pathway. This article assumes you hold it or are on track to hold it. If you do not, confirm your position against the specialty specific guidance before building your portfolio strategy around this route.

The five evidence pillars

The haematology curriculum, as reflected in the GMC Specialty Specific Guidance and the RCPath Portfolio Pathway guidance, maps to five principal evidence areas. They are not equal in weight, and they are not all equally easy to document, but all five must be addressed. An application with gaps in any pillar is likely to attract a deferral request, and the deferral requests for haematology tend to be specific and require targeted supplementary evidence rather than a general uplift.

Blood morphology and diagnostic haematology

Blood film morphology is the foundational diagnostic skill of haematology, and it is also one of the evidence items most commonly under-documented. Most haematologists interpret significant numbers of films every week, but the documentation of that work rarely reaches portfolio standard unless it is captured deliberately. A letter from your laboratory manager confirming the volume of films you review annually is supporting context. It is not evidence of morphological competence.

Building a morphology log

A contemporaneous morphology log - maintained consistently throughout your evidence period, not started six months before submission - is the primary evidence item for this pillar. The log does not need to capture every film you report; it needs to capture the cases that demonstrate the breadth and quality of your morphological practice. Each entry should record the date, the clinical context, your morphological findings stratified by red cell, white cell, and platelet abnormalities, and the diagnostic conclusion or action taken.

Aim for 100 to 200 significant case entries over your evidence period, with a spread across red cell disorders, leukaemia and lymphoma, thrombocytopenia and platelet abnormalities, and reactive or infective changes. Cases that prompted a bone marrow examination or that had direct clinical management consequences are the most valuable entries, because they demonstrate morphological diagnosis translating into clinical action - the clearest demonstration of consultant-level practice.

EQA participation for morphology

UK NEQAS for Haematology operates a morphology External Quality Assurance scheme that distributes digitised and physical blood film specimens for identification and differential count. Participation under your own individual identifier is the single most objective quality marker available for the morphology pillar, because it provides an externally generated score that is independent of your own account of your practice. Your performance on distributed specimens - how your identifications compare to the expert consensus answer - is the kind of verifiable quality marker that RCPath assessors can rely on without having to take your word for it.

If you are not currently participating in EQA under your own name, register now. EQA attributed to the laboratory as a whole carries far less evidential weight than data attributed to you individually. Details of the relevant schemes are available from UK NEQAS. The earlier you enrol, the more distribution cycles you can include in your evidence log.

Bone marrow procedures and trephine reporting

Bone marrow work generates two parallel evidence streams that are sometimes confused: the procedural logbook and the diagnostic reporting log. Both are required, and they evidence different curriculum capabilities. The procedural logbook demonstrates that you can safely and competently perform bone marrow aspirates and trephine biopsies at consultant level. The reporting log demonstrates that you can interpret and report the samples produced by those procedures and by others.

Bone marrow procedure logbook

The logbook should record each procedure you perform, under supervision or independently, with the following minimum data points: the date, the clinical indication (staging, diagnosis, remission assessment, transplant evaluation), the procedure type (aspirate alone, trephine alone, combined), the approach (posterior iliac crest, anterior iliac crest, sternum - with sternal reserved for specific indications), any complications or difficulties, and your role at the time (supervised, performed with oversight, or independent).

DOPS assessments for bone marrow procedures need to come from a senior colleague who has directly observed you performing the procedure. The DOPS should cover: your technique (patient positioning, site selection, anaesthesia, advancement technique), your communication with the patient before, during, and after the procedure, your handling of complications or difficulties, and the quality of the sample obtained. A DOPS completed by someone who was in the room but not directly observing your technique is weaker than one completed by someone who watched the whole procedure from preparation to post-procedure instructions.

Coagulation and haemostasis evidence

Coagulation and haemostasis sits at the boundary of laboratory and clinical haematology in a way that is unique within the specialty. The laboratory side involves interpreting complex coagulation screens, investigating clotting factor deficiencies, thrombophilia workups, platelet function studies, and coagulation inhibitor assays. The clinical side involves managing patients with haemophilia, von Willebrand disease, hereditary thrombophilia, antiphospholipid syndrome, immune thrombocytopenic purpura (ITP), and acquired coagulopathies. Evidence needs to demonstrate both sides.

Laboratory coagulation evidence

Your laboratory information system records the coagulation tests processed and authorised under your identifier, and a named personal report from the LIS covering your log period provides volume and variety evidence for basic coagulation testing. For complex coagulation work, a case-based log is more persuasive than aggregate LIS data, because it allows you to show your diagnostic reasoning on the individual cases that required consultant-level interpretation - the prolonged APTT that needed a mixing study and factor assay, the patient with a discrepant INR and factor activity, the workup for a patient with unexplained arterial thrombosis in a young woman.

A log of 30 to 50 complex coagulation workup cases over your evidence period, stratified by diagnostic category (acquired coagulopathy, hereditary bleeding disorder investigation, thrombophilia screen, coagulation inhibitor), provides credible laboratory haemostasis evidence. Each entry should note the clinical question, the tests performed in sequence, your interpretation at each step, and the final diagnosis or management decision.

Clinical haemostasis evidence

For the clinical haemostasis pillar, the most important evidence item is a haemostasis clinic log - a record of new and follow-up patients you have managed in an outpatient haemostasis or inherited bleeding disorder setting. For haematologists working in a centre with a haemophilia comprehensive care team, this log will include patients with haemophilia A and B, von Willebrand disease of different subtypes, and rarer factor deficiencies. For those without a dedicated haemophilia service, the clinic log may focus on general haemostasis referrals: abnormal preoperative clotting screens, thrombocytopenia workup, antiphospholipid syndrome management, and warfarin or direct oral anticoagulant decisions.

VTE management is a high-volume area for most clinical haematologists, and evidence of consultant-level decision-making in anticoagulation - including cases involving thrombophilia screening, heparin-induced thrombocytopenia (HIT), catastrophic antiphospholipid syndrome, or unusual VTE presentations - is directly mappable to the haemostasis and thrombosis curriculum CiPs. CbD assessments focused on complex anticoagulation management cases are strong verified evidence for this component of the pillar.

Clinical haematology: MDTs, clinics, and wards

The clinical haematology pillar is where many haematologists feel most confident, because this is the domain in which they practise every day. The evidence challenge is not generating the clinical activity - it is documenting it at the standard required for portfolio evidence rather than merely showing that it happened.

Haemato-oncology MDT participation

The haematological malignancy MDT is one of the most important single evidence items in a haematology Portfolio Pathway application. Most UK NHS haematology departments run regular MDTs covering lymphoma, myeloma, acute leukaemia, MDS and MPN, and chronic myeloid disorders. Regular, senior participation in one or more of these MDTs is a curriculum requirement, not an optional enrichment activity.

What differentiates MDT evidence from MDT attendance is reflection and specificity. An attendance certificate confirming you were present at 47 MDT meetings over two years says you showed up. A reflective log covering 20 to 30 specific cases from those MDTs - noting the diagnostic question, the morphological or haematological findings you contributed, the treatment decision reached, and what the case taught you about haemato-oncology MDT practice - says you contributed clinically. The two documents together are far stronger than either alone.

Outpatient clinic evidence

Outpatient clinic evidence demonstrates your independent clinical practice in the haematology setting. The most credible clinic documentation is a clinic log extracted from your electronic patient record system, combined with reflective entries on selected complex new referrals and challenging follow-up cases. The clinic log should show: new referral volume by diagnosis category (haemato-oncology, benign haematology, haemostasis, general), follow-up attendance, and an indication of the complexity range you manage independently.

If you do not have direct access to a clinic log from your electronic patient record, a letter from your clinical manager or service lead confirming your clinic sessions and patient volume, combined with your own case-based reflective log, provides an acceptable alternative. What is not acceptable is a claim of outpatient clinical practice without any corroborating documentation. The multi-source feedback guide covers how colleague feedback from clinic staff and co-workers in the outpatient setting can complement your clinical evidence.

Inpatient haematology and acute presentations

Acute haematological presentations - TTP, DIC, febrile neutropenia, acute leukaemia with hyperleukocytosis, sickle cell crisis, immune haemolytic anaemia - are where haematology Consultant-level decision-making is most clearly demonstrated. Cases managed acutely, particularly those where your prompt clinical decision-making changed the management course, are among the most compelling evidence items in a haematology application.

Document acute inpatient cases contemporaneously. A brief structured note for each significant acute haematology episode you manage - clinical presentation, diagnostic assessment, your clinical decisions, outcome, and a reflective sentence on the case - generates a log of acute haematology management evidence that is far more persuasive than a general claim of inpatient haematology experience. Target 20 to 30 acute episode entries over your log period, covering the range of haematological emergencies, not just the most common. Cases where you liaised with critical care, surgery, obstetrics, or the blood bank for a complex transfusion case demonstrate cross-specialty working, which is a separate CiP area.

Transfusion medicine evidence

Transfusion medicine is the pillar most commonly treated as an afterthought in haematology Portfolio Pathway applications. There are two reasons for this: haematologists who work primarily in a clinical role may feel that transfusion is primarily a blood bank function, and the governance and advisory nature of much transfusion consultant work makes it less visible in personal records than clinical haematology activity. Neither of these is an excuse for thin transfusion evidence in a haematology application. The RCPath curriculum explicitly requires competence in transfusion medicine as a distinct CiP area.

Hospital transfusion committee and governance

The most straightforward transfusion evidence to generate is your role in hospital transfusion governance. Most NHS trusts have a hospital transfusion committee (HTC) or equivalent that meets regularly to review transfusion practice, consider serious adverse events, review blood component usage data, and ensure MHRA and SaBTO compliance. Membership, attendance, and documented advisory contributions to your HTC over your evidence period is strong, independently verifiable transfusion governance evidence.

What you need from HTC participation is not just proof of attendance. Meeting minutes that record your specific contributions - a recommendation you made about prescribing guidelines, a serious adverse event investigation you presented, a policy change you proposed - provide evidence of consultant-level transfusion governance involvement. A letter from your Trust's transfusion practitioner or transfusion manager confirming your advisory role and the specific contributions you have made over your log period is a direct reference for this pillar.

Serious transfusion reactions and near-miss investigations

Serious hazards of transfusion (SHOT) reporting and near-miss reviews generate strong transfusion evidence because they document your clinical involvement in a specific, traceable, patient safety-focused process. If you have led or contributed to a serious transfusion reaction investigation - an acute haemolytic reaction, a TACO or TRALI case, an anaphylactic reaction - the investigation report in which you are named as the haematology lead or investigator is excellent portfolio evidence. Root cause analyses and action plans following near-miss events (incorrect blood component transfused, wrong patient identification, compatibility error) similarly demonstrate consultant-level transfusion responsibility.

Haematologists who work in a clinical haematology role without direct blood bank responsibility should not conclude that they have no transfusion evidence to gather. Clinical transfusion decisions - authorising special requirements (irradiated components for immunocompromised patients, CMV-negative products, phenotyped red cells), managing massive haemorrhage calls, advising on elective surgical patients with complex haematological backgrounds - are all clinical transfusion practice, and they generate evidence without requiring you to work in the blood bank.

FRCPath and its role in the application

FRCPath in Haematology by examination is a mandatory prerequisite for the haematology Portfolio Pathway. The examination is delivered by the Royal College of Pathologists and is divided into two parts: Part 1 (written, covering the scientific basis and clinical principles of haematology and blood transfusion) and Part 2 (practical and case-based, covering morphology, haemostasis, blood transfusion, and clinical haematology through written and structured oral components).

FRCPath is not just a tick-box for the application. It serves a dual function: it confirms that your knowledge meets the RCPath standard independent of your portfolio evidence, and it covers areas of the curriculum - particularly morphology examination, coagulation testing principles, and transfusion immunology - that would otherwise be difficult to verify through documentary portfolio evidence alone. For some haematologists, the FRCPath examination process itself generates useful study material, morphology practice, and engagement with the haematology literature that directly strengthens their portfolio evidence strategies.

For Portfolio Pathway applicants who hold FRCPath examinations from outside the UK, the equivalence assessment is a separate process. The RCPath accepts FRCPath from its sister colleges in Hong Kong and Singapore and holds equivalence arrangements with a small number of other pathology boards. If your haematology qualification is from a system outside these arrangements, confirm the position with the RCPath directly before building your evidence strategy. The specialty specific guidance article explains how to read and use SSG documents for evidence planning.

The ten-year evidence window

Pathology specialties, including haematology, generally operate a ten-year evidence window rather than the five-year window that applies to most clinical specialties. This is a significant practical advantage for haematologists who have been practising at consultant level for many years without having previously assembled a formal portfolio, because evidence going back a decade carries full weight under the RCPath Portfolio Pathway guidance.

The ten-year window does not mean that older evidence is as valuable as recent evidence. RCPath assessors are looking for current assurance of your practice standards, and an application in which the bulk of the evidence is more than five years old will raise questions about currency. The ten-year window means that older evidence can fill in curriculum areas that may have been part of your earlier practice and are less central to your current role. A bone marrow transplant case log from eight years ago at a transplanting centre remains valid evidence even if you now work in a district general hospital that does not transplant.

Where a specific curriculum capability - for example, certain specialised laboratory techniques or a procedure now rarely performed at your Trust - is primarily evidenced by work from more than five years ago, include it with a brief contextual explanation. A note that the technique has been superseded or that your Trust now refers this work to a regional centre is more credible than leaving the assessor to wonder why there is no recent evidence in that area. Honesty about scope changes is not a weakness if it is clearly explained. The recent evidence and the five-year rule article covers this in detail for all specialties.

How to balance and present both sides

The practical question most haematologists face when assembling their portfolio is how to present a coherent narrative across five evidence pillars that span very different types of clinical and laboratory work. The answer is not to merge them - it is to structure them separately and connect them explicitly.

Common weak spots and deferral triggers

Based on the pattern of deferral requests and RCPath assessor feedback documented in published haematology training literature and the RCPath Portfolio Pathway guidance, the following are the most frequently cited weak areas in haematology applications.

Morphology evidence without EQA. A morphology log is necessary but not sufficient. Without EQA participation data under your own identifier, the log is self-reported. Adding UK NEQAS morphology data provides the independent quality marker that assessors need to verify your self-reported competence. If you have been meaning to enrol in EQA for years but have not, enrol now.

MDT reflections that describe decisions rather than contributions. The difference between "the MDT decided to treat with RCHOP" and "I presented the immunophenotype data, reviewed the morphological classification, and the diagnostic discussion I contributed to changed the working diagnosis from DLBCL to a follicular lymphoma grade 3B, altering the treatment pathway" is the difference between an attendance record and portfolio evidence. Your personal contribution to the MDT discussion is what needs evidencing.

Transfusion governance that is entirely advisory rather than documented. Many haematologists serve as the clinical lead for transfusion at their Trust in an informal or advisory capacity without a formal role title or regular HTC membership. If this is your situation, formalise it. Request a formal appointment to the HTC if you do not have one, start attending regularly, and ensure your contributions are recorded in meeting minutes. Advisory work that leaves no documentary trace cannot be evidenced.

Coagulation evidence concentrated on thrombosis rather than bleeding. VTE management is accessible and high volume for most haematologists, but applications that evidence coagulation and haemostasis entirely through anticoagulation management and thrombophilia screening, without any evidence from the inherited bleeding disorder or complex coagulation laboratory side, have a visible gap. The significant event analysis guide covers how to document complex haemostasis management cases effectively.

A thin bone marrow reporting log. Bone marrow trephine reporting is a distinct curriculum requirement from bone marrow procedures. A logbook of procedures performed, without evidence of independent trephine report writing, misses a separate CiP. If your reporting experience is limited, a structured arrangement to join reporting sessions with a histopathology or haematopathology colleague, with a senior sign-off on your reports, is a tractable way to build this evidence stream.

All 18 specialisms

The haematology Portfolio Pathway overview and other specialism guides are below. Each is built around the relevant GMC SSG and RCPath or Royal College guidance.

Where this sits in the haematology sequence

This article covers evidence documentation strategy. The supporting guides below provide the broader haematology Portfolio Pathway context and the cross-specialty evidence tools you will need alongside these specialty-specific pillar strategies.